(Q42269559)

19 October 2017

title

Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model (English)

1 reference

19 October 2017

0 references

1 reference

1 reference

8

Dick van Soolingen

1 reference

19 October 2017

6

Henri A Verbrugh

1 reference

Irma A. J. M. Bakker-Woudenberg

19 October 2017

9

object named as

Irma A J M Bakker-Woudenberg

1 reference

19 October 2017

7

Martin J Boeree

1 reference

19 October 2017

author name string

Jurriaan E M de Steenwinkel

1

1 reference

19 October 2017

Rob E Aarnoutse

2

1 reference

19 October 2017

Gerjo J de Knegt

3

1 reference

19 October 2017

Marian T ten Kate

4

1 reference

19 October 2017

Marga Teulen

5

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

American Journal of Respiratory and Critical Care Medicine

19 October 2017

published in

1 reference

19 October 2017

volume

187

1 reference

19 October 2017

issue

10

1 reference

19 October 2017

page(s)

1127-1134

1 reference

Drugs in development for tuberculosis

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Mycobacterium tuberculosis Beijing genotype is an independent risk factor for tuberculosis treatment failure in Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Clinical Pharmacokinetics of Rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Metabolism and pharmacokinetics of the antibiotic rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

A physiologically based pharmacokinetic model of rifampin in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201207-1210OC

10.1164/RCCM.201207-1210OC

21 January 2018

Identifiers

DOI

1 reference

19 October 2017

1 reference